Table 4.
Cost of 15-week ESAs treatment (6-cycles chemotherapy) for responder &non responder patients receiving originators or biosimilars per Hb level
| |
|
|
Responders |
Non responders |
Responders |
Non responders |
Cost difference for responders originators vs. Biosimilars (€) | Cost difference for non responders originators vs. Biosimilars (€) | Total difference originators vs. Biosimilars (€) |
|---|---|---|---|---|---|---|---|---|---|
| HB Nadir (g/dl) | % of patients per Hb level | Number of Greek patients treated with ESAs per Hb Level | Cost of 15 weeks treatment with originator ESAs (€) | Cost of 15 weeks treatment with originator ESAs (€) | Cost of 15 weeks treatment with Biosimilar ESAs (€) | Cost of 15 weeks treatment with Biosimilar ESAs (€) | |||
| <9 |
33.5 |
855 |
1.233.547 |
2.144.861 |
1.120.816 |
1.713.324 |
112.731 |
431.537 |
544.268 |
| 9.0-9.9 |
27.5 |
701 |
1.012.613 |
1.760.707 |
920.072 |
1.406.460 |
92.541 |
354.247 |
446.787 |
| 10.0-10.9 |
24.7 |
630 |
909.511 |
1.581.435 |
826.392 |
1.263.257 |
83.118 |
318.178 |
401.296 |
| 11.0-11.9 |
9.5 |
242 |
349.812 |
608.244 |
317.843 |
485.868 |
31.969 |
122.376 |
154.345 |
| >12.0 |
4.8 |
122 |
176.747 |
307.323 |
160.594 |
245.491 |
16.153 |
61.832 |
77.985 |
| Total | 100 | 2.551 | 3.682.229 | 6.402.570 | 3.345.718 | 5.114.400 | 336.511 | 1.288.170 | 1.624.681 |